{"id":"NCT03116685","sponsor":"OxThera","briefTitle":"A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria","officialTitle":"A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-01-09","primaryCompletion":"2021-04-15","completion":"2021-04-15","firstPosted":"2017-04-17","resultsPosted":"2021-12-09","lastUpdate":"2021-12-10"},"enrollment":25,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Primary Hyperoxaluria"],"interventions":[{"type":"BIOLOGICAL","name":"Oxabact OC5 - Oxalobacter formigenes HC-1","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Oxabact OC5 capsules","type":"EXPERIMENTAL"},{"label":"Placebo capsules","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the efficacy and safety of OC5 in patients with PH.","primaryOutcome":{"measure":"Change From Baseline in Plasma Oxalate Concentration After 52 Weeks of Treatment","timeFrame":"52 weeks","effectByArm":[{"arm":"Oxabact OC5 Capsules","deltaMin":14.8,"sd":5.7},{"arm":"Placebo Capsules","deltaMin":14.4,"sd":5.4}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["United States","Belgium","France","Germany","Spain","Tunisia","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":13},"commonTop":["Vomiting","Nasopharyngitis","Tonsillitis","Flank pain","Pyrexia"]}}